The drug for the coronavirus “MIR-19” admitted to the second phase of research
The drug for the prevention and treatment of coronavirus infection “MIR-19”, developed by the Federal Biomedical Agency, received permission for the second phase of clinical trials, RIA Novosti reports, citing a statement by the head of the FMBA, Veronica Skvortsova.
She clarified that the duration of this phase will be several months. Registration of the drug is expected by the end of 2021.
Skvortsova said that the tests of MIR-19, carried out on animals and in cell culture, proved the safety of the drug and its high efficiency. According to the head of the FMBA, MIR-19 can reduce the viral load by ten thousand times, which makes this drug actually an antidote.
As a reminder, on April 11, the FMBA Institute of Immunology Research Center received a patent for the Mir-19 drug. Its name stands for small interfering RNA. The drug is expected to inhibit the replication of the virus and prevent the most severe forms of COVID-19.
